atai-backed Beckley Psytech unveils positive results from DMT for treatment-resistant depression studyProactive Investors • 03/27/24
atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionGlobeNewsWire • 03/27/24
atai Life Sciences doses first patient in Phase 1b study of its optimized oral DMT formulationProactive Investors • 03/04/24
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01GlobeNewsWire • 03/04/24
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/28/24
Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health RevolutionInvestorPlace • 01/09/24
atai Life Sciences expands its pipeline with $50M investment in Beckley PsytechProactive Investors • 01/05/24
Psychedelic firm atai Life Sciences expands its pipeline with $50M investment in Beckley PsytechProactive Investors • 01/04/24
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration PsychedelicsGlobeNewsWire • 01/04/24
Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash ValueSeeking Alpha • 11/29/23
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline HighlightsGlobeNewsWire • 11/14/23
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitGlobeNewsWire • 10/06/23
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ParticipantsGlobeNewsWire • 10/02/23
Psychedelics CEOs heartened by MDMA for PTSD study results as stocks maintain momentumProactive Investors • 09/15/23
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/14/23
atai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 09/06/23
Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved TherapiesSeeking Alpha • 09/01/23
Down -24.4% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)Zacks Investment Research • 08/21/23
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)GlobeNewsWire • 08/10/23